Tissue Med Biosciences (TMB) is an Austrian biotech company that develops novel, recombinant human protein-based products for the treatment of chronic degenerative diseases.TMB selected a topical application for its initial product: the proprietary technology employs a human protein with growth factor characteristics, enabling for the first time, not only faster wound healing, but also complete wound healing, even for larger chronic wounds. In addition, TMB has a product pipeline in place, which is placed on its proprietary technology and consists of eight product candidates for the therapy musculoskeletal diseases, cardiovascular diseases and oncology.
